TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Tofacitinib for the Treatment of Alopecia Areata and Its Variants

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age \>= 18 years old~* Diagnosis of alopecia areata with \>50% scalp involvement, alopecia totalis, or alopecia universalis~* Hair loss present for at least 6 months~* No treatment for alopecia areata in past 2 months~* No evidence of hair regrowth~* Females of childbearing potential must use birth control while taking the medication and there must be a negative pregnancy test documented prior to starting the medication~* Fluent in spoken and written English~Exclusion Criteria:~* Age \<18 years old~* Patients have received treatment known to affect alopecia areata within 2 months of enrolling in the study~* Patients with a history of malignancy (except history of successfully treated basal cell or squamous cell carcinoma of the skin)~* Patients known to be HIV or hepatitis B or C positive~* Patients with positive tuberculin skin test or positive QuantiFERON TB test~* Patients with leukopenia or anemia~* Patients with renal or hepatic impairment~* Patients with peptic ulcer disease~* Patients taking immunosuppressive medications, including but not limited to prednisone, methotrexate, mycophenolate mofetil, azathioprine, tacrolimus, cyclosporine, or TNH-alpha inhibitors~* Women of childbearing potential who are unable or unwilling to use birth control while taking the medication~* Women who are pregnant or nursing

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Tofacitinib (Type: EXPERIMENTAL): Participants will receive tofacitinib for 3 months.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Budesonide / Formoterol Combination in Repeated AMP Provocations

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* asthma diagnosis according to ATS criteria,~* lung function (FEV1) above 60% of predicted,~* AMP-PC20 below 160 mg/ml with a documented fall in FEV1 of 30% in this provocation test~Exclusion Criteria:~* having smoked \> 10 Pack-years,~* hypersensitivity to one of the study drugs,~* significant co-morbidity, pregnancy or lactating

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Validation Durability Adenosine Effect in Verification Pulmonary Vein Isolation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients undergoing atrial fibrillation ablation, pulmonary vein isolation by catheter for standard clinical indications~Exclusion Criteria:~* allergy or contraindication to adenosine,~* inability to give informed consent,~* currently taking dipyridamole,~* verapamil or theophylline and~* breast-feeding mothers.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Adenosine arm (Type: EXPERIMENTAL): 25 patients will be randomized to received 2 doses of adenosine 12 mg IV, 5 minutes apart after pulmonary vein isolation. During this time, will monitor for pulmonary vein reconnection, second dose of adenosine will be given only if no reconnection after initial dose.
- Observation arm (Type: NO_INTERVENTION): 25 patients will be randomized to 10 minute period of observation for pulmonary vein reconnection after documentation of pulmonary vein isolation. This will serve as the control arm.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comparing Omeprazole With Fluoxetine for Treatment of Non Erosive Reflux Disease and Its Subgroups: a Double-blind Placebo-controlled Clinical Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2/PHASE3
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* age above 18 and below 60 years old~* experiencing heartburn during last 6 months before inclusion~* experiencing heartburn during at least 4 of 7 days before inclusion~* presence of normal mucosa in upper gastrointestinal(GI) endoscopy which has been documented during 7 days before inclusion provided that the patient has not administered any PPI during last 30 days before inclusion~Exclusion Criteria:~* inability to undergone upper GI endoscopy or PH monitoring~* presence of barret's esophagus or erosive esophagitis in upper GI endoscopy~* presence of active peptic ulcer disease or any disease which affects the absorption of drugs such as inflammatory bowel disease~* past history of esophageal or gastric surgery~* esophageal stricture which needs dilation~* administration of proton pomp inhibitors during 30 days before inclusion to the study~* administration of H2 blockers, anticholinergics, sucralfate and pro-kinetics during the assessments for eligibility and also during the study~* long time administration of non-steroidal anti-inflammatory drugs (NSAIDs)~* administration of neuroleptic or antidepressant drugs during 30 days before inclusion to the study~* known allergy to PPIs or SSRIs~* presence of significant systemic disease such as scleroderma , diabet mellitus , peripheral and autonomic neuropathies and ...~* pregnancy for females~* presence of known psychiatric disorder such as depression , panic disorder or drug addiction according to the DSM-IV criteria

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- pH positive-omeprazole (Type: ACTIVE_COMPARATOR): None
- pH positive-placebo (Type: PLACEBO_COMPARATOR): None
- pH positive-fluoxetine (Type: ACTIVE_COMPARATOR): None
- pH negative-omeprazole (Type: ACTIVE_COMPARATOR): None
- pH negative-fluoxetine (Type: ACTIVE_COMPARATOR): None
- pH negative-placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Retrospective Study Evaluating the Efficacy and Safety of Micafungin Sodium in the Treatment of Invasive Fungal Infections

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients who received Micafungin as empirical antifungal therapy, pre-emptive antifungal therapy, diagnostic driven antifungal therapy or targeted antifungal therapy~* Patients received Micafungin treatment at least 1 dose~Exclusion Criteria:~* Patients received Micafungin treatment combined with other antifungal drugs at the same time~* Neither efficacy or safety can be evaluated because of missing data, confused record

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Micafungin group (Type: None): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate Efficacy and Safety of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Fixed Dose Combination (FDC) Versus a Regimen Consisting of Darunavir/Cobicistat FDC With Emtricitabine/Tenofovir Disoproxil Fumarate FDC in Treatment-naive HIV Type 1 Infected Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subject must be antiretroviral (ARV) treatment-naive (never treated with an ARV including post-exposure prophylaxis and pre-exposure prophylaxis); no prior use of any approved or experimental anti- human immunodeficiency virus (anti-HIV) drug for any length of time~* Screening plasma HIV-1 ribonucleic acid (RNA) level greater than or equal to \>=1,000 copies per milliliter (copies/mL)~* Cluster of Differentiation 4+ (CD4+) cell count \>50 cells/microliter (cells/mcL)~* Screening HIV-1 genotype report must show full sensitivity to DRV, TDF and FTC~* Screening eGFRcreatinine \>=70 mL/min according to the Cockcroft-Gault formula for creatinine clearance~Exclusion Criteria:~* Subject has been diagnosed with a new acquired immunodeficiency syndrome (AIDS)-defining condition within the 30 days prior to screening~* Subject has proven or suspected acute hepatitis within 30 days prior to screening~* Subject is hepatitis C or hepatitis B positive~* Subject has a history of cirrhosis

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (Type: EXPERIMENTAL): Subject will receive a single oral tablet containing darunavir (DRV) 800 milligram (mg)/ cobicistat (COBI) 150 mg/ emtricitabine (FTC) 200 mg/ tenofovir alafenamide (TAF) 10 mg (D/C/F/TAF fixed dose combination \[FDC\]) once daily along with DRV/COBI FDC-matching and FTC/TDF FDC-matching placebo tablets once daily up to Week 48 analysis unblinding visit (i.e. after last subject has reached Week 48). After Week 48 analysis unblinding visit, subjects will receive a single tablet containing D/C/F/TAF FDC once daily up to Week 96.
- DRV/COBI fixed dose combination (FDC) and FTC/TDF FDC (Type: ACTIVE_COMPARATOR): Subject will receive DRV 800 mg/COBI 150 mg FDC and FTC 200 mg/TDF 300 mg FDC along with D/C/F/TAF FDC-matching placebo tablet once daily up to Week 48 analysis unblinding (i.e. after last subject has reached Week 48). After Week 48 analysis unblinding, subjects will receive a single tablet containing D/C/F/TAF FDC once daily up to Week 96.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study Evaluating Antibody Response Of 13-Valent Pneumococcal Conjugate Vaccine (13vPnC) 24 Months After Toddler Dose.

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy subjects at least 3 years of age, who received all 4 assigned doses of pneumococcal conjugate vaccine and completed Study 6096A1-008-EU (NCT00366678) for at least 24 months~Exclusion Criteria:~* Vaccination with any licensed or investigational pneumococcal vaccine since completion of Study 6096A1-008-EU(NCT00366678).~* History of culture-proven invasive disease caused by S pneumoniae since the completion of Study 6096A1-008-EU (NCT00366678).~* Previous anaphylactic reaction to any vaccine or vaccine-related component.~* Contraindication to vaccination

- Gender: ALL
- Minimum Age: 3 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- 1 (Type: EXPERIMENTAL): 1 dose (0.5 mL), IM of 13vPnC vaccine.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of In-the-bag Stability Between Single-piece and Three-piece Intraocular Lens

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* diagnosis of bilateral age-related cataract and age between 60 to 85 years~Exclusion Criteria:~* vision-impairing diseases other than cataract, severe refractive error (Preoperative spherical equivalent of either eye \>-6.00D or +5.00D)~* history of ocular trauma, past refractive surgery or other ophthalmic surgery, capsular or zonular disorders that might affect the post-operative centration of IOLs~* surgical complications including severe hyphema, iris injury, repeated IOL implantation~* unable to achieve in-the-bag implantation of IOL, corneal sutures during surgery

- Gender: ALL
- Minimum Age: 60 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Single-piece IOL Group (Type: EXPERIMENTAL): Age-related cataract patients receive in-the-bag implantation of a single-piece IOL
- Three-piece IOL Group (Type: EXPERIMENTAL): Age-related cataract patients receive in-the-bag implantation of a three-piece IOL

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Duloxetine vs. Placebo in the Treatment of Osteoarthritis Knee Pain

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female outpatients with osteoarthritis knee pain.~Exclusion Criteria:~* Serious cardiovascular, hepatic, renal, respiratory, or hematologic illness, or other medical or psychiatric condition that, in the opinion of the investigator, would compromise participation or be likely to lead to hospitalization during the course of the study.~* Previous exposure to duloxetine.

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- A (Type: EXPERIMENTAL): None
- B (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Booster Dose of Ad5-EBOV in Healthy Adults After Primary Immunization

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Participants who enrolled in the initial study, and completed the primary vaccination.~* Able to understand the content of the additional informed consent and willing to sign the additional informed consent for the boosting study~* Able and willing to complete a one-month follow-up.~* HIV negative~* Axillary temperature ≤37.0°C on the day of enrollment~* General good health as established by medical history and physical examination.~Exclusion Criteria:~New occurrence of any of the following situation after the primary vaccination:~* Subject that has a medical history of any of the following: allergic history of any vaccination or drugs, or allergic to any ingredient of the Ad5-EBOV vaccine, such as mannitol~* Woman who become pregnant after the primary vaccination or is positive in β-HCG (human chorionic gonadotropin) pregnancy test (urine) on day of enrollment for the boosting study~* Any acute fever disease or infections in last 7 days~* Not well-controlled chronic illness, such as asthma, diabetes, or thyroid disease~* Hereditary angioneurotic edema or acquired angioneurotic edema~* Urticaria in last 6 months~* Asplenia or functional asplenia~* Platelet disorder or other bleeding disorder may cause injection contraindication~* Faint at the sight of blood or needles.~* Prior administration of immunodepressant or corticosteroids, antianaphylaxis treatment, cytotoxic treatment in last 6 months~* Prior administration of blood products in last 4 months~* Prior administration of other research medicines in last 1 month~* Prior administration of attenuated vaccine in last 1 month~* Prior administration of inactivated vaccine in last 14 days~* Current anti-tuberculosis prophylaxis or therapy~* Any condition that in the opinion of the investigators may interfere with the evaluation of study objectives

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: t

Study Arms:
- low dose group (Type: EXPERIMENTAL): 4×10\^10vp/1ml Ebola Zaire vaccine (Ad5-EBOV)
- high dose group (Type: EXPERIMENTAL): 1.6×10\^11vp/2ml Ebola Zaire vaccine (Ad5-EBOV)
- placebo group (Type: PLACEBO_COMPARATOR): placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Tools for Health and Resilience Implemented After Violence Exposure (Project THRIVE)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* informed consent~* self-identification as female~* sexual assault, defined as endorsement of unwanted, attempted or completed sexual contact in the past 10 weeks~* age \> 18~* English fluency~* smartphone and internet access at least daily for 3 weeks and at least weekly for 3 months~* consumption of \>1 alcoholic drink in the past month~* \>1 episode of high-risk drinking in past 6 months, defined as either more than 3 drinks on a given day or more than 7 drinks in a given week~* at least 3 symptom clusters endorsed on the PTSD Checklist.~Exclusion Criteria:~* active suicidality~* psychosis

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Intervention (Type: EXPERIMENTAL): The THRIVE app involves 3 weeks of daily activities. Day 1 involves identification of activities to add to a self-care activity list with guidance around selecting activities that increase social contact, reduce alcohol use, and reduce avoidance. They will also complete an active-learning exercise about cognitive distortions and create a stuck point to-do list consisting of their cognitive distortions. In subsequent days, participants will be prompted to complete activities from both lists. They will also have access optional activities on topics such as asking for help, preventing isolation, deciding whether to disclose an assault, coping with negative reactions to disclosure, and thinking in helpful ways about social support. They will be prompted to complete brief daily surveys in the app, which will populate a symptom tracker. Participants in will have brief weekly phone contact with a coach to monitor safety and troubleshoot issues with app use.
- Assessment-only control (Type: NO_INTERVENTION): The assessment-only control condition will involve access to a version of the app that includes daily surveys and a symptom tracker populated by these surveys, but without any of the other exercises included in the experimental version of the app. Participants in the control condition will have brief weekly phone contact with a coach to monitor safety and troubleshoot issues with app use.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Informal Caregivers ANSWERS-VA

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Informal caregiver of a family member or friend (Veteran) with a stroke or TBI~* Caregiver must express need or concerns in providing care~* Plans to be providing care for 1 year or longer~* Access to telephone~* Willingness to participate in 9 call from a nurse and 5 data collection calls at designated timepoints~* Veteran's stroke must be within past 3 years~* Veteran's TBI must be since 9/11/01~Exclusion Criteria:~* Caregiver or survivor age \< 18 years~* Caregiver denies that survivor has had a stroke or a TBI~* Caregiver does not consider him or herself a caregiver, stating that the survivor is not impaired or is the same as before the stroke or TBI~* Caregiver has low task difficulty (OCBS task difficulty score \< 16)~* Caregiver communication difficulties (e.g., hearing loss)~* Caregiver not fluent in the English language~* Caregiver with serious medical illness limiting ability to participate~* Caregiver refuses to sign a HIPAA authorization allowing the VA to store personal health information (PHI) in a location outside the VA~* Survivor residing in a nursing home or long-term care facility~* Survivor or caregiver has a terminal illness (e.g., cancer, end of life condition with decreased life expectancy, renal failure requiring dialysis)~* Survivor or caregiver history of hospitalization for alcohol or drug abuse~* Survivor or caregiver history of Alzheimer's, dementia, suicidal tendencies, severe untreated depression or manic depressive disorder, or schizophrenia.~* Survivor or caregiver pregnancy~* Survivor or caregiver is a prisoner or on house arrest~* Survivor had a Transient Ischemic Attack (rather than a hemorrhagic or ischemic stroke)~* Survivor had a stroke more than 3 years ago

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- ANSWERS-VA (Type: EXPERIMENTAL): 8 week telephone intervention with nurse case manager using Acquiring New Skills While Enhancing Remaining Strengths (ANSWERS)
- Control (Type: OTHER): 8 week telephone usual care with education with nurse case manager

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete